Tini, Elvira; Smigielski, Lukasz; Romanos, Marcel; Wewetzer, Christoph; Karwautz, Andreas; Reitzle, Karl; Correll, Christoph U; Plener, Paul L; Malzahn, Uwe; Heuschmann, Peter; Unterecker, Stefan; Scherf-Clavel, Maike; Rock, Hans; Antony, Gisela; Briegel, Wolfgang; Fleischhaker, Christian; Banaschewski, Tobias; Hellenschmidt, Tobias; Imgart, Hartmut; Kaess, Michael; ... (2022). Therapeutic drug monitoring of sertraline in children and adolescents: A naturalistic study with insights into the clinical response and treatment of obsessive-compulsive disorder. Comprehensive psychiatry, 115, p. 152301. Elsevier 10.1016/j.comppsych.2022.152301
|
Text
1-s2.0-S0010440X22000074-main.pdf - Published Version Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND). Download (2MB) | Preview |
BACKGROUND
Sertraline is a selective serotonin reuptake inhibitor with specific indications in child and adolescent psychiatry. Notwithstanding its frequent use and clinical benefits, the relationship between pharmacokinetics, pharmacodynamics, efficacy, and tolerability of sertraline across indications, particularly in non-adult patients, is not fully understood.
METHOD
This naturalistic therapeutic drug monitoring (TDM) study was conducted in a transdiagnostic sample of children and adolescents treated with sertraline (n = 78; mean age, 14.22 ± 2.39; range, 7-18 years) within the prospective multicenter "TDM-VIGIL" project. Associations between dose, serum concentration, and medication-specific therapeutic and side effects based on the Clinical Global Impression scale were examined. Tolerability was measured qualitatively with the 56-item Pediatric Adverse Event Rating Scale.
RESULTS
A strong linear positive dose-serum concentration relationship (with dose explaining 45% of the variance in concentration) and significant effects of weight and co-medication were found. Neither dose nor serum concentration were associated with side effects. An overall mild-to-moderate tolerability profile of sertraline was observed. In contrast with the transdiagnostic analysis that did not indicate an effect of concentration, when split into depression (MDD) and obsessive-compulsive disorder (OCD) diagnoses, the probability of clinical improvement significantly increased as both dose and concentration increased for OCD, but not for MDD.
CONCLUSIONS
This TDM-flexible-dose study revealed a significant diagnosis-specific effect between sertraline serum concentration and clinical efficacy for pediatric OCD. While TDM already guides clinical decision-making regarding compliance, dose calibration, and drug-drug interactions, combining TDM with other methods, such as pharmacogenetics, may facilitate a personalized medicine approach in psychiatry.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > University Psychiatric Services > University Hospital of Child and Adolescent Psychiatry and Psychotherapy |
UniBE Contributor: |
Kaess, Michael |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
0010-440X |
Publisher: |
Elsevier |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
08 Mar 2022 13:47 |
Last Modified: |
05 Dec 2022 16:13 |
Publisher DOI: |
10.1016/j.comppsych.2022.152301 |
PubMed ID: |
35248877 |
Uncontrolled Keywords: |
TDM antidepressants pharmacovigilance selective serotonin reuptake inhibitors steady state concentration |
BORIS DOI: |
10.48350/166754 |
URI: |
https://boris.unibe.ch/id/eprint/166754 |
Actions (login required)
 |
Edit item |